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nephritis or diabetic nephropathy) participating in con-
trolled, randomized clinical trials to be automatically
transferred to everyday clinical practice. The general
population is getting increasingly older every year, and
the majority of treated patients are elderly subjects with
nephroangiosclerosis and little or no proteinuria, with no
actual possibility for checking for renal artery stenosis. We
should remember, for example, what the RALES study
taught us about the risk of hyperkalemia when its results
were translated into everyday clinical practice.4
Another aspect we wanted to underline was that we
should not only look at deteriorating renal function but
also (and above all) cardiovascular prevention, because
many more chronic kidney disease patients in the general
population die before needing dialysis than actually start
chronic dialysis even in the most advanced stages of the
disease.5,6 This is a rather different scenario from what is
observed in randomized, controlled clinical trials, and
further underlines the need for randomized clinical studies
of older patients with more comorbidities and a greater
likelihood of vascular disease as the cause of their chronic
kidney disease. Such studies should consider cardiovascu-
lar as well as renal end points in order to evaluate the cost-
effectiveness of RASI administration in such a non-selected
patient population.
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To the Editor: In their interesting study, Kakiya et al.1 found
that a higher fat mass index was associated with lower
mortality rate in hemodialysis patients. Moreover, fat mass
index was positively correlated with total cholesterol in the
studied group. As the authors mention, malnutrition in
dialysis population often coexists with inflammation.
Furthermore, it is well known that ‘reverse epidemiology’
found for fat mass index is also observed for serum
cholesterol level and is also associated with inflammation in
this population.2
Recently, we tried to investigate cholesterol–inflammation
relationship in hemodialysis patients. We found that the
production of soluble components of interleukin-6 (inter-
leukin-6, soluble interleukin-6 receptor, and soluble
gp130) from activated peripheral blood mononuclear cells
isolated from hypocholesterolemic hemodialysis patients is
higher than the production of the same molecules from
monocytes isolated from hyper-cholesterolemic patients.3 In
case our data are confirmed in similar studies, it seems
that hypo-cholesterolemia – and potentially low fat mass – is
not simply associated but may also be causally related
to the production of soluble components of a crucial
proinflammatory and potentially atherogenic cytokine, as
interleukin-6, by an also crucial for atherosclerotic process
cell type, namely the circulating monocyte. Cellular choles-
terol depletion may be the link connecting hypo-cholester-
olemia and increased interleukin-6 components’
production.4
Thus, as the study of Kakiya et al. showed, ‘reverse
epidemiology’ regarding low fat mass – and potentially
hypo-cholesterolemia – is a reality that may also be causally
linked to the high inflammatory activity observed in this
population; this later hyper-reactivity may be implicated
in the evolution of processes like atherosclerosis,5 which
explain lower survival of hemodialysis patients with low fat
mass.
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